Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170150 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07170150 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 800 participants, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT07170150, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Trontinemab
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- K2 Medical Research-Winter Garden - Clermont
- Visionary Investigators Network- Neurology Aventura - Miami
- Charter Research - Winter Park/Orlando - Orlando
- Conquest Research - Lake Nona - Orlando
- Alzheimer's Research and Treatment Center - Stuart
California
- Sun Valley Research Center, Inc. - Imperial
- Healthy Brain Clinic - Long Beach
- Oakland Clinical - Oakland
- Riverside Clinical - Riverside
- Cenexel California Neuroscience Research, LLC - Sherman Oaks
Georgia
- CenExel iResearch, LLC - Decatur
- Center for Advanced Research & Education - Gainesville
Arizona
- Banner Alzheimer?s Institute - Phoenix
Connecticut
- Yale University - New Haven
Illinois
- Great Lakes Clinical Trials Chicago d/b/a Flourish Research Andersonville - Chicago
Massachusetts
- Adams Clinical Watertown - Watertown
Michigan
- Quest Research Institute - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07170150
The ClinicalTrials.gov registry entry for NCT07170150 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,056-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (80% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07170150 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07170150 about?
NCT07170150 is a clinical study titled "A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease". The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
What is the current status of trial NCT07170150?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-11-12. Estimated completion is 2028-06-07.
What conditions does trial NCT07170150 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07170150?
The interventions under investigation include: Placebo (OTHER), Trontinemab (DRUG).
Who is sponsoring clinical trial NCT07170150?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07170150 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.